Literature DB >> 15590471

Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin.

Flemming Staubach1, Veronika Nober, Peter Janknecht.   

Abstract

PURPOSE: Facilitation of vitrectomy by vitreolytic enzymes may be of great value in complicated or office-procedure vitreo-retinal surgery. In this study, we quantified and compared the effect of hyaluronidase, chondroitinase, and plasmin pre-incubation on vitrectomy rate and explored potential retinal damage.
METHODS: Freshly enucleated pigs eyes were incubated (1 or 3 hours) with an intravitreally injected enzyme or control solution. Enzyme doses were 100 and 1000 U for hyaluronidase, 1 and 2 U for chondroitinase, 3 and 30 U for plasmin. The eyes were weighed before and after 10 minutes of one-port vitrectomy, the difference representing the amount of removed vitreous. Light microscopy was used to assess potential damage to the retina.
RESULTS: All enzymes significantly increased the amount of removed vitreous at all doses and incubation periods. The highest increase was found with hyaluronidase 1000 U, 3 hours, the lowest with chondroitinase 1 U, 1 hour. Damage occasionally occurred to the internal limiting membrane and very rarely to the nerve fiber layer. No damage at all was seen in the 100 and 1000 U hyaluronidase (1-hour incubation) groups.
CONCLUSIONS: Hyaluronidase, chondroitinase, and plasmin are good candidates for enzyme-assisted vitrectomy. Although retinal structural damage was very rarely seen, safety concerns will have to be investigated further.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15590471     DOI: 10.1080/02713680490516747

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  10 in total

1.  Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study.

Authors:  Martin Hermel; Norbert F Schrage
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

2.  Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo.

Authors:  Martin Hermel; Jonathan Prenner; Motaz Alabdulrazzak; Wendy Dailey; Michael Hartzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

3.  Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels.

Authors:  Polly A Quiram; Victor R Leverenz; Robert M Baker; Loan Dang; Frauk J Giblin; Michael T Trese
Journal:  Retina       Date:  2007-10       Impact factor: 4.256

4.  Preservation of structure and immunoreactivity at the vitreoretinal interface of the rabbit eye.

Authors:  Bruce A Pfeffer; Steven A Bernstein; Stephen P Bartels
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-20       Impact factor: 3.117

5.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

6.  Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.

Authors:  Jasmina Cehajic-Kapetanovic; Magali M Le Goff; Annette Allen; Robert J Lucas; Paul N Bishop
Journal:  Mol Vis       Date:  2011-06-30       Impact factor: 2.367

7.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01

Review 8.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17

Review 9.  Ocriplasmin for vitreoretinal diseases.

Authors:  Irena Tsui; Carolyn K Pan; Ehsan Rahimy; Steven D Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-10-14

10.  Efficacy and Safety of Glycosidic Enzymes for Improved Gene Delivery to the Retina following Intravitreal Injection in Mice.

Authors:  Jasmina Cehajic-Kapetanovic; Nina Milosavljevic; Robert A Bedford; Robert J Lucas; Paul N Bishop
Journal:  Mol Ther Methods Clin Dev       Date:  2017-12-22       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.